Parkinson's disease Alzheimers disease and other types of dementia Cardiovascular diseases F00 F01 G30 F03 F02 I60 I61 I62 I63 I64 G20
Conditions
Interventions
Group 1: Control group:
Recieves standard therapy during hospitalisation.
Additionally, after inclusion and before discharge, data will be gathered via the SF-36 questionnaire, a question from the tec
Sponsors
Schön Klinik Bad Aibling SE & Co. KG
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: PATIENTS General • Age =60 years; • Have a caregiver or reference person. • Sufficient cognition capabilities to take informed decisions. • Acceptance to participate and have signed the informed consents. • Agree to use the provided devices; • Understand local language; • Ability to walk (with or without walking aids) or able to use wheelchair; • Compliance with scenario setting. AD • Patient with Alzheimer Disease accordingly to the NINCDS-ADRDA criteria or diagnosed dementia with MMSE score of 19 to 28; PD • Patients with confirmed diagnosis of Parkinson Disease accordingly to the criteria by United Kingdom Parkinson’s Disease Brain Bank (UKPDSBB) criteria or according to a neurological assessment; CVD • Patient that presents one of the following: o Cardiovascular failure grade II-III NYHA; o Coronary heart disease: both stable and acute coronary artery disease (ACS) with or without ST elevation; o Atrial Fibrillation; o Cardiac Pacemaker Carrier; o Cerebral Stroke; • Preserved language comprehension and communication skills. CAREGIVER General • To be able to consent and to comply with at least one of the following requisites: o To be employed by a public or private company or directly by the patients to provide direct care and thus support daily activities. o To live with and/or take care of a relative (or other close relationship) affected by Parkinson’s disease or Alzheimer’s disease or/and others dementia or CVD o To provide logistic support to a family member or a close friend affected by Parkinson’s disease or Alzheimer’s disease or/and others dementia or CVD. • Express readiness in the use of technologies to use the devices PROFESSIONALS General • To be able to consent and to be qualified and working in a medical or social area specialized in the care or support of Parkinson’s, Alzheimer’s or/and dementia and cardiovascular diseases (including general practitioners, nurses, social workers and others).
Exclusion criteria
Exclusion criteria: PATIENTS General Patients whose caregiver is unwilling to participate / assist; Patients / caregivers are unwilling to work with the technologies used in this project. AD • Advanced stages of the disease (for example Alzheimer’s disease: avoid GDS 6-7). • Patients with acute stroke in the previous six months (Hachinski scale score > 4); • Pyramidal and or Extrapyramidal signs at neurological examinations; • Patients’ whom informal carer (family care giver) is not willing to participate/assist; • Patients/carer is unwilling to work with technologies used in this project; • Advanced stage of disease. PD • Parkinsonism syndromes (Multiple System Atrophy (MSA) Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS) • Dementia with Lewy bodies (DLB) • Patients with secondary parkinsonisms; • Patients’ whom informal carer (family care giver) is not willing to participate/assist; • Patients/carer is unwilling to work with technologies used in this project; • Advanced stage of disease. CVD • Patients’ whom informal carer (family care giver) is not willing to participate/assist; • Patients/carer is unwilling to work with technologies used in this project • ACS less than 4 weeks ago; • Severe aortic stenosis; • Severe visual or hearing impairment. CAREGIVER General • Caregivers not able to consent. • Caregivers not aware of the daily needs of PROFESSIONALS General • Not working as a professional involved in the care or support of AD, PD, CVD patients. • Working practice and environment not connected to Alzheimer’s’, Parkinson’s’ and other dementias. • Conflict of interest. • Not to be able to consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Data gathering via the SF-36 questionnaire (quality of life) | — |
Secondary
| Measure | Time frame |
|---|---|
| Usability of the TeNDER system (questionnaire of usability "User Experience Questionnaire") | — |
Countries
Germany
Contacts
Public ContactBarbara Schaepers
Schön Klinik Bad Aibling SE & Co. KG
Outcome results
None listed